Brii Biosciences Limited
BRIBF
Get informed when a big investor buys or sells
+ FollowMarket Cap$620.21M
Close$
$0.11
17.5% downside
Current Fair Value
17.5% downsideOvervalued by 17.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $620.21 Million |
|---|---|
| Enterprise Value | $122.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 1.2 |
| Outstanding Shares | 734,400,000 |
Return
| Return on Equity | -24.54% |
|---|---|
| Return on Assets | -24.72% |
| Return on Invested Capital | -29.03% |
Valuation & Multiples
| P/E Ratio | -3.07 |
|---|---|
| PEG | 9.28 |
| Price to Sales | - |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | 2.37 |
| Enterprise Value to EBIT | -0.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Brii Biosciences Limited
80 employees
CEO: Zhi Hong Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline feat...